Qualigen Therapeutics, Inc.

NasdaqCM QLGN

Qualigen Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025

Qualigen Therapeutics, Inc. Free Cash Flow Yield is NA on January 14, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Qualigen Therapeutics, Inc. 52-week high Free Cash Flow Yield is -3,519.04% on February 26, 2024, which is NA below the current Free Cash Flow Yield.
Qualigen Therapeutics, Inc. 52-week low Free Cash Flow Yield is -5,755.63% on March 19, 2024, which is NA below the current Free Cash Flow Yield.
Qualigen Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -4,519.19%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: QLGN

Qualigen Therapeutics, Inc.

CEO	Mr. Kevin A. Richardson II
IPO Date	June 23, 2015
Location	United States
Headquarters	2042 Corte Del Nogal
Employees	4
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key trends

Past 5 years